PMC:7299399 / 12677-13670 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T62","span":{"begin":771,"end":800},"obj":"Body_part"},{"id":"T63","span":{"begin":771,"end":786},"obj":"Body_part"},{"id":"T64","span":{"begin":802,"end":806},"obj":"Body_part"},{"id":"T65","span":{"begin":839,"end":843},"obj":"Body_part"},{"id":"T66","span":{"begin":938,"end":952},"obj":"Body_part"},{"id":"T67","span":{"begin":938,"end":942},"obj":"Body_part"}],"attributes":[{"id":"A62","pred":"fma_id","subj":"T62","obj":"http://purl.org/sig/ont/fma/fma82834"},{"id":"A63","pred":"fma_id","subj":"T63","obj":"http://purl.org/sig/ont/fma/fma63023"},{"id":"A64","pred":"fma_id","subj":"T64","obj":"http://purl.org/sig/ont/fma/fma82834"},{"id":"A65","pred":"fma_id","subj":"T65","obj":"http://purl.org/sig/ont/fma/fma82834"},{"id":"A66","pred":"fma_id","subj":"T66","obj":"http://purl.org/sig/ont/fma/fma63841"},{"id":"A67","pred":"fma_id","subj":"T67","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Moreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the development of broad-spectrum drugs, which could potentially offer some efficacy against future emerging viruses (and maybe SARS-CoV-2). The various approaches developed over the years are mainly based on the creation of entry inhibitors.40,41 A highly conserved part in viruses is the attachment ligand (VAL). In most known respiratory viruses,42 the VAL targets either heparan sulfate proteoglycans (HSPG)43 or sialic acids (SA).44 Both HSPG and SA mimics have shown in vitro ability to bind to viruses, blocking their interaction with cell membranes, and often in a broad-spectrum way.45−47"}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T59","span":{"begin":33,"end":41},"obj":"Disease"},{"id":"T60","span":{"begin":524,"end":532},"obj":"Disease"}],"attributes":[{"id":"A59","pred":"mondo_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Moreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the development of broad-spectrum drugs, which could potentially offer some efficacy against future emerging viruses (and maybe SARS-CoV-2). The various approaches developed over the years are mainly based on the creation of entry inhibitors.40,41 A highly conserved part in viruses is the attachment ligand (VAL). In most known respiratory viruses,42 the VAL targets either heparan sulfate proteoglycans (HSPG)43 or sialic acids (SA).44 Both HSPG and SA mimics have shown in vitro ability to bind to viruses, blocking their interaction with cell membranes, and often in a broad-spectrum way.45−47"}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T140","span":{"begin":44,"end":47},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T141","span":{"begin":188,"end":189},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T142","span":{"begin":242,"end":247},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T143","span":{"begin":270,"end":271},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T144","span":{"begin":276,"end":281},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T145","span":{"begin":385,"end":392},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T146","span":{"begin":505,"end":512},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T147","span":{"begin":644,"end":645},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T148","span":{"begin":671,"end":678},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T149","span":{"begin":705,"end":708},"obj":"http://purl.obolibrary.org/obo/CLO_0037067"},{"id":"T150","span":{"begin":737,"end":744},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T151","span":{"begin":752,"end":755},"obj":"http://purl.obolibrary.org/obo/CLO_0037067"},{"id":"T152","span":{"begin":771,"end":800},"obj":"http://purl.obolibrary.org/obo/PR_000001307"},{"id":"T153","span":{"begin":802,"end":806},"obj":"http://purl.obolibrary.org/obo/PR_000001307"},{"id":"T154","span":{"begin":839,"end":843},"obj":"http://purl.obolibrary.org/obo/PR_000001307"},{"id":"T155","span":{"begin":897,"end":904},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T156","span":{"begin":938,"end":942},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T157","span":{"begin":943,"end":952},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T158","span":{"begin":967,"end":968},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T159","span":{"begin":988,"end":990},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"}],"text":"Moreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the development of broad-spectrum drugs, which could potentially offer some efficacy against future emerging viruses (and maybe SARS-CoV-2). The various approaches developed over the years are mainly based on the creation of entry inhibitors.40,41 A highly conserved part in viruses is the attachment ligand (VAL). In most known respiratory viruses,42 the VAL targets either heparan sulfate proteoglycans (HSPG)43 or sialic acids (SA).44 Both HSPG and SA mimics have shown in vitro ability to bind to viruses, blocking their interaction with cell membranes, and often in a broad-spectrum way.45−47"}

LitCovid-PD-CHEBI

LitCovid-PD-GlycoEpitope

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":771,"end":786},"obj":"GlycoEpitope"}],"attributes":[{"id":"A1","pred":"glyco_epitope_db_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0086"}],"text":"Moreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the development of broad-spectrum drugs, which could potentially offer some efficacy against future emerging viruses (and maybe SARS-CoV-2). The various approaches developed over the years are mainly based on the creation of entry inhibitors.40,41 A highly conserved part in viruses is the attachment ligand (VAL). In most known respiratory viruses,42 the VAL targets either heparan sulfate proteoglycans (HSPG)43 or sialic acids (SA).44 Both HSPG and SA mimics have shown in vitro ability to bind to viruses, blocking their interaction with cell membranes, and often in a broad-spectrum way.45−47"}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T61","span":{"begin":0,"end":160},"obj":"Sentence"},{"id":"T62","span":{"begin":161,"end":257},"obj":"Sentence"},{"id":"T63","span":{"begin":258,"end":352},"obj":"Sentence"},{"id":"T64","span":{"begin":353,"end":536},"obj":"Sentence"},{"id":"T65","span":{"begin":537,"end":710},"obj":"Sentence"},{"id":"T66","span":{"begin":711,"end":993},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Moreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the development of broad-spectrum drugs, which could potentially offer some efficacy against future emerging viruses (and maybe SARS-CoV-2). The various approaches developed over the years are mainly based on the creation of entry inhibitors.40,41 A highly conserved part in viruses is the attachment ligand (VAL). In most known respiratory viruses,42 the VAL targets either heparan sulfate proteoglycans (HSPG)43 or sialic acids (SA).44 Both HSPG and SA mimics have shown in vitro ability to bind to viruses, blocking their interaction with cell membranes, and often in a broad-spectrum way.45−47"}

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"217","span":{"begin":839,"end":843},"obj":"Gene"},{"id":"218","span":{"begin":802,"end":806},"obj":"Gene"},{"id":"219","span":{"begin":33,"end":43},"obj":"Species"},{"id":"220","span":{"begin":524,"end":534},"obj":"Species"},{"id":"221","span":{"begin":725,"end":736},"obj":"Species"},{"id":"222","span":{"begin":705,"end":708},"obj":"Chemical"},{"id":"223","span":{"begin":752,"end":755},"obj":"Chemical"},{"id":"224","span":{"begin":771,"end":786},"obj":"Chemical"},{"id":"225","span":{"begin":813,"end":825},"obj":"Chemical"},{"id":"226","span":{"begin":827,"end":829},"obj":"Chemical"},{"id":"227","span":{"begin":848,"end":850},"obj":"Chemical"}],"attributes":[{"id":"A217","pred":"tao:has_database_id","subj":"217","obj":"Gene:6383"},{"id":"A218","pred":"tao:has_database_id","subj":"218","obj":"Gene:6383"},{"id":"A219","pred":"tao:has_database_id","subj":"219","obj":"Tax:2697049"},{"id":"A220","pred":"tao:has_database_id","subj":"220","obj":"Tax:2697049"},{"id":"A221","pred":"tao:has_database_id","subj":"221","obj":"Tax:12814"},{"id":"A224","pred":"tao:has_database_id","subj":"224","obj":"MESH:D006497"},{"id":"A225","pred":"tao:has_database_id","subj":"225","obj":"MESH:D012794"},{"id":"A226","pred":"tao:has_database_id","subj":"226","obj":"MESH:D012794"},{"id":"A227","pred":"tao:has_database_id","subj":"227","obj":"MESH:D012794"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Moreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the development of broad-spectrum drugs, which could potentially offer some efficacy against future emerging viruses (and maybe SARS-CoV-2). The various approaches developed over the years are mainly based on the creation of entry inhibitors.40,41 A highly conserved part in viruses is the attachment ligand (VAL). In most known respiratory viruses,42 the VAL targets either heparan sulfate proteoglycans (HSPG)43 or sialic acids (SA).44 Both HSPG and SA mimics have shown in vitro ability to bind to viruses, blocking their interaction with cell membranes, and often in a broad-spectrum way.45−47"}

2_test

{"project":"2_test","denotations":[{"id":"32519842-25263223-158471","span":{"begin":831,"end":833},"obj":"25263223"},{"id":"32519842-21384484-158472","span":{"begin":988,"end":990},"obj":"21384484"},{"id":"32519842-19447134-158473","span":{"begin":991,"end":993},"obj":"19447134"}],"text":"Moreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the development of broad-spectrum drugs, which could potentially offer some efficacy against future emerging viruses (and maybe SARS-CoV-2). The various approaches developed over the years are mainly based on the creation of entry inhibitors.40,41 A highly conserved part in viruses is the attachment ligand (VAL). In most known respiratory viruses,42 the VAL targets either heparan sulfate proteoglycans (HSPG)43 or sialic acids (SA).44 Both HSPG and SA mimics have shown in vitro ability to bind to viruses, blocking their interaction with cell membranes, and often in a broad-spectrum way.45−47"}

PMC:7299399 / 12677-13670 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7299399 / 12677-13670 JSON TXT